(NASDAQ: CTXR) Citius Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.6%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.33%.
Citius Pharmaceuticals's earnings in 2025 is -$43,095,563.On average, 1 Wall Street analyst forecast CTXR's earnings for 2025 to be -$41,572,953, with the lowest CTXR earnings forecast at -$41,572,953, and the highest CTXR earnings forecast at -$41,572,953.
In 2026, CTXR is forecast to generate -$2,058,067 in earnings, with the lowest earnings forecast at -$2,058,067 and the highest earnings forecast at -$2,058,067.